Trial Profile
BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Ipatasertib (Primary) ; Paclitaxel (Primary)
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms BARBICAN
- 10 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2018 New trial record